The company’s stock fell $2.70 on July 21, 2026, closing at $37.36 after officials confirmed the drug failed to demonstrate the clinical differentiation necessary to justify further investment. Agios had been testing the therapy in patients aged 16 or older suffering from sickle cell disease before abruptly halting the program.

Pomerantz LLP, a firm specializing in corporate and securities class litigation, is now soliciting contact from affected investors to determine if officers or directors misled shareholders regarding the drug's prospects. Investors seeking to participate in the inquiry may reach Danielle Peyton at 646-581-9980, extension 7980, or via email at dpeytone@pomlaw.com.